The AI-based diagnostic software system allows to detect, grade and measure prostate tumours in biopsies obtained from patients at risk of prostate cancer
The partnership will receive £36m to study the system. (Credit: Business Wire)
AI-based diagnostic software provider Paige, Oxford University and the UK’s National Health Service (NHS) regional partners have secured government funding to study Paige Prostate cancer detection system.
The partnership will receive £36m under the Phase 4 Artificial Intelligence in Health and Care award from the NHS Accelerated Access Collaborative to evaluate Paige Prostate prospectively in a real-world cancer laboratory setting.
The funding will help leaders in uropathology at Oxford University Hospitals, Coventry and Warwickshire University Hospitals Trust, and North Bristol Trust, to design system adoption guidelines for Paige Prostate.
Paige Prostate is a clinical-grade artificial intelligence (AI)-based diagnostic software system, which allows pathologists to detect, grade and measure prostate tumours in biopsies secured from patients at risk of prostate cancer and other similar systems.
Paige Prostate secured CE mark approval for use in laboratories and hospitals in the European Economic Area, Switzerland and the UK. It also secured breakthrough device designation from the US Food and Drug Administration (FDA).
The adoption guidelines will allow the further launch of AI technologies and advanced algorithms across the NHS to help diagnose complex diseases.
Paige CEO Dr Leo Grady said: “Paige is proud to be working with this multidisciplinary team of experts to demonstrate the impact of digital pathology tools in routine clinical use.
“Alongside our partners, we look forward to potentially ushering in a new era of clinical diagnostics powered by AI-enabled technologies to benefit patients and cellular pathology laboratories throughout the NHS.”
The Phase 4 award, which is limited to mature market-authorised CE-IVD products, will allow Paige and its partners to demonstrate clinical or economic use of Paige Prostate with respect to its real-world implementation and use in the NHS.
The partnership also intends to show clinical and economic impact of Paige Prostate in the NHS and social care setting.
In January this year, Paige secured $100m in a Series C funding round to advance the transformation of digital pathology by leveraging insights from patient’s sample.